Amgen And Bioeq Shuttle Stelara Biosimilars Into Phase III Trials
Amgen Study Involves FDA-Approved Product
Almost in tandem, Amgen and Bioeq, with partner Formycon, have advanced their biosimilar Stelara (ustekinumab) candidates into Phase III clinical trials. Both sponsors are aiming to wrap their studies up in 2022.
